OncoGenex Pharmaceuticals to Present at Upcoming Investor Conference
BOTHELL, WA and VANCOUVER, May 28, 2013
BOTHELL, WA and VANCOUVER, May 28, 2013 /PRNewswire/ - OncoGenex
Pharmaceuticals, Inc.(NASDAQ: OGXI) announced today that Scott Cormack,
President and Chief Executive Officer, will provide a corporate presentation
at the Jefferies 2013 Healthcare Conference on Tuesday, June 4 , 2013 at 8:00
a.m. ET at the Grand Hyatt Hotel in New York City.
A live audio webcast can be accessed through the Investor Relations page of
the OncoGenex website atwww.oncogenex.com. The webcast replay will be
archived for 60 days.
OncoGenex is a biopharmaceutical company committed to the development and
commercialization of new therapies that address treatment resistance in cancer
patients. OncoGenex has a diverse oncology pipeline, with each product
candidate having a distinct mechanism of action and representing a unique
opportunity for cancer drug development.OncoGenexandTeva Pharmaceutical
Industries Ltd.have entered a global collaboration and license agreement to
develop and commercialize OncoGenex' lead drug candidate, custirsen. Custirsen
is currently in Phase 3 clinical development as a treatment in men with
metastatic castrate-resistant prostate cancer and in patients with advanced,
unresectable non-small cell lung cancer. OGX-427 is in Phase 2 clinical
development and OGX-225 is currently in pre-clinical development. More
information is available at www.OncoGenex.com.
SOURCE OncoGenex Pharmaceuticals, Inc.
Investor Relations Contact:
Press spacebar to pause and continue. Press esc to stop.